Scarica l'app Stockscreener
206.87
0.00%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$206.86
Aprire:
$207.48
Volume 24 ore:
1.35M
Relative Volume:
1.24
Capitalizzazione di mercato:
$22.81B
Reddito:
$10.52B
Utile/perdita netta:
$999.00M
Rapporto P/E:
24.74
EPS:
8.3628
Flusso di cassa netto:
$1.22B
1 W Prestazione:
+8.47%
1M Prestazione:
+14.95%
6M Prestazione:
+15.54%
1 anno Prestazione:
+22.61%
Intervallo 1D:
$204.58
$209.39
Intervallo di 1 settimana:
$187.58
$213.20
Portata 52W:
$157.20
$213.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
206.87 | 22.80B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Rhumbline Advisers Decreases Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
ING Groep NV Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86 - Yahoo Finance
Quest Diagnostics Incorporated $DGX Shares Sold by Cookson Peirce & Co. Inc. - MarketBeat
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics PT to $235 From $210, Maintains Outperform Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics - Benzinga
DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds - Finviz
Quest Diagnostics (DGX): Truist Securities Raises Price Target A - GuruFocus
UBS Raises Price Target for Quest Diagnostics (DGX) to $210 | DG - GuruFocus
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating - marketscreener.com
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News - GuruFocus
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Evercore ISI Adjusts Quest Diagnostics PT to $220 From $190, Maintains In Line Rating - marketscreener.com
Barclays Adjusts Quest Diagnostics PT to $225 From $210, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $219 From $203, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript - Insider Monkey
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220 - GuruFocus
Truist Raises Price Target on Quest Diagnostics to $220 From $205, Keeps Hold Rating - marketscreener.com
Candriam S.C.A. Has $13.69 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised - AlphaStreet News
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026 - Meyka
Quest Diagnostics: Q4 Earnings Snapshot - theheraldreview.com
Why Is Quest (DGX) Stock Soaring Today - Finviz
Quest Diagnostics (DGX) Earnings Call Transcript - The Globe and Mail
Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: St - GuruFocus
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue - Finviz
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up - sharewise.com
Quest Diagnostics (DGX) Sees Significant Stock Price Surge - GuruFocus
Quest Diagnostics Incorporated announces an Increase in Equity Buyback - marketscreener.com
Quest Diagnostics Stock Gains 7% Over Increased Profit In Q4 - Nasdaq
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - marketscreener.com
Quest Diagnostics hits 52-week high on outlook (DGX:NYSE) - Seeking Alpha
Quest Diagnostics (NYSE:DGX) Sets New 12-Month High Following Strong Earnings - MarketBeat
Quest Diagnostics stock hits all-time high at $198.00 By Investing.com - Investing.com Canada
Quest Diagnostics stock hits all-time high at $198.00 - Investing.com
Quest Diagnostics Seeks Independent Lab Acquisitions - marketscreener.com
Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand - marketscreener.com
Quest Diagnostics (NYSE:DGX) Issues Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance - MarketBeat
Quest Diagnostics: Fourth Quarter Earnings Overview - bitget.com
Quest Diagnostics Q4 Adjusted Earnings, Revenue Rise; 2026 Guidance Set -- Shares Up Pre-Bell - marketscreener.com
Quest Diagnostics Posts Strong 2025 Results, Boosts Shareholder Returns - TipRanks
(DGX) Quest Diagnostics Expects 2026 Revenue Range $11.7B$11.82B, vs. FactSet Est of $11.38B - marketscreener.com
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.63%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):